Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Virginia L. Filiaci"'
Autor:
Kristina W. Thiel, Eric J. Devor, Virginia L. Filiaci, David Mutch, Katherine Moxley, Angeles Alvarez Secord, Krishnansu S. Tewari, Megan E. McDonald, Cara Mathews, Casey Cosgrove, Summer Dewdney, Carol Aghajanian, Megan I. Samuelson, Heather A. Lankes, Robert A. Soslow, Kimberly K. Leslie
Publikováno v:
Journal of Clinical Oncology. 40:3289-3300
PURPOSE The status of p53 in a tumor can be inferred by next-generation sequencing (NGS) or by immunohistochemistry (IHC). We examined the association between p53 IHC and sequence and whether p53 IHC alone, or integrated with TP53 NGS, predicts the o
Autor:
Matthew A. Powell, Virginia L. Filiaci, Martee L. Hensley, Helen Q. Huang, Kathleen N. Moore, Krishnansu S. Tewari, Larry J. Copeland, Angeles A. Secord, David G. Mutch, Alessandro Santin, David P. Warshal, Nick M. Spirtos, Paul A. DiSilvestro, Olga B. Ioffe, David S. Miller
Publikováno v:
J Clin Oncol
PURPOSE This phase III randomized trial ( NCT00954174 ) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to paclitaxel and ifosfamide (PI) for treating uterine carcinosarcoma (UCS). PATIENTS AND METHODS Adults with chemothe
Autor:
Cara Mathews, Xun Clare Zhou, Peter G. Rose, Virginia L. Filiaci, Michael T. McHale, Amanda Jackson, Heather A. Lankes, Debra L. Richardson, Douglas A. Levine, Carol Aghajanian, Angeles Alvarez Secord, Krishnansu S. Tewari, Kimberly K. Leslie, Casey Cosgrove, Katherine M. Moxley, Summer B. Dewdney, Yovanni Casablanca, David G. Mutch, Eric J. Devor, Megan E McDonald, Kristina W. Thiel, Adrianne R. Mallen
Publikováno v:
Gynecol Oncol
Background Successfully combining targeted agents with chemotherapy is an important future goal for cancer therapy. However, an improvement in patient outcomes requires an enhanced understanding of the tumor biomarkers that predict for drug sensitivi
Autor:
Ursula A. Matulonis, Helen Q. Huang, Virginia L. Filiaci, Marcus Randall, Paul A. DiSilvestro, Katherine M. Moxley, Jeffrey M. Fowler, Matthew A. Powell, Nick M. Spirtos, Krishnansu S. Tewari, William E. Richards, John M. Nakayama, David G. Mutch, David S. Miller, Daniela Matei, Lari B. Wenzel
Publikováno v:
Gynecol Oncol
INTRODUCTION: Chemotherapy plus radiation (Cis-RT+CP) did not demonstrate superiority in prolonging relapse-free survival compared to chemotherapy alone in patients with stage III or IVA endometrial carcinoma. The impact of treatment on quality of li
Autor:
Brian M. Slomovitz, Virginia L. Filiaci, Joan L. Walker, Michael C. Taub, Karen A. Finkelstein, John W. Moroney, Aimee C. Fleury, Carolyn Y. Muller, Laura L. Holman, Larry J. Copeland, David S. Miller, Robert L. Coleman
Publikováno v:
Gynecologic oncology. 164(3)
Blocking the PI3K/AKT/mTOR pathway decreases resistance to hormonal therapy in endometrial carcinoma (EC).In this study, the aim was to assess the efficacy and tolerability of everolimus(E)/letrozole (L) or medroxyprogesterone acetate(M)/tamoxifen(T)
Autor:
Nick M. Spirtos, James J. Burke, David Miller, Jae Weon Kim, Marcus E. Randall, Paul DiSilvestro, Robert S. Mannel, Virginia L. Filiaci, Penny R. Anderson, William Small, Ritu Salani, Keith Terada, Helen J. Huang, Wendy R. Brewster, Vivian E. von Gruenigen, Carol Aghajanian, Catheryn M. Yashar, D. Scott McMeekin, Thomas J. Rutherford
Publikováno v:
Journal of Clinical Oncology. 37:1810-1818
PURPOSE The primary objective was to determine if vaginal cuff brachytherapy and chemotherapy (VCB/C) increases recurrence-free survival (RFS) compared with pelvic radiation therapy (RT) in high-intermediate and high-risk early-stage endometrial carc
Autor:
Yong M. Kim, Daniela Matei, William Small, Margaret M. Steinhoff, Krishnansu S. Tewari, David Miller, Nick M. Spirtos, John Nakayama, Virginia L. Filiaci, Paul DiSilvestro, Katherine M. Moxley, William E. Richards, Ursula A. Matulonis, David M. O'Malley, David G. Mutch, Helen Q. Huang, Matthew A. Powell, Marcus E. Randall
Publikováno v:
New England Journal of Medicine. 380:2317-2326
BACKGROUND: Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence. METHODS: In this randomized phase 3 trial, we tested whether 6 months of platinum-based chemotherapy plus radiation therapy (chemoradi
Autor:
Tatyana A. Grushko, Marsha A. Apushkin, Michael J. Birrer, Virginia L. Filiaci, Olufunmilayo I. Olopade, Carlton Schwab, Nilsa C. Ramirez, Laura Monovich, Shelly Seward, Maria J. Gomez, Joshua Kesterson, Gini F. Fleming, Michael W. Method, Anthony G. Montag
Publikováno v:
Appl Immunohistochem Mol Morphol
We performed a pilot study in anticipation of using long-aged precut formalin-fixed paraffin-embedded tissue sections stored in real-world conditions for translational biomarker studies of topoisomerase 2A (TOP2A), Ki67, and human epidermal growth fa
Autor:
Michael L. Pearl, Emily K. Hill, Joan L. Walker, William H. Rodgers, Virginia L. Filiaci, Heather A. Lankes, Kimberly K. Leslie, Elise C. Kohn, Kari L. Ring, Anand Rajan, Carolyn Y. Muller, Laura L. Holman, Linda R. Duska, Christina L. Kushnir, Richard G. Moore, Kelley Carrick, Megan I. Samuelson, Richard Piekarz
Publikováno v:
Clin Cancer Res
Purpose: This surgical window of opportunity (window) study assessed the short-term effect of medroxyprogesterone acetate (MPA) alone versus MPA plus the histone deacetylase (HDAC) inhibitor entinostat on regulation of progesterone receptor (PR) in w
Autor:
Krishnansu S. Tewari, Angeles Alvarez Secord, Carol Aghajanian, Robert A. Soslow, Matthew A. Powell, Virginia L. Filiaci, Heather A. Lankes, Fanny Dao, Don S. Dizon, Douglas A. Levine, Ashley Stuckey, Jianjiong Gao, Kathleen N. Moore, David M. O'Malley, David Bender, Jay W. Carlson
Publikováno v:
Gynecologic Oncology. 150:274-281
OBJECTIVE: Paclitaxel and carboplatin (PC) is a standard initial therapy for advanced endometrial cancer. We evaluated the efficacy and tolerability of incorporating three novel agents into initial therapy. METHODS: In this randomized phase II trial,